ESMC · Escalon Medical Corp
$0.18
+0.01 (+6.06%)
At close · Sep 1
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the twelve months following issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$1.26M
Shares
7.42M
ESMC metrics
65 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.18
Market cap
$1.26M
Price action
19 metricsPrice change (1W)
+0.0%
Price change (30D)
-7.9%
Price change (3M)
-12.5%
Price change (6M)
-16.7%
Price change (YTD)
+2.9%
Price change (1Y)
-37.5%
Trailing year
Price change (5Y)
+16.7%
52-week high
$0.35
52-week low
$0.12
Change from 52-week high
-50.0%
Change from 52-week low
+45.8%
Annualized volatility
196.5%
Beta
2.6
RSI (14D)
46.8
Price vs SMA 50
-9.5%
Price vs SMA 200
-23.9%
Avg volume (3M)
10,410
Relative volume
0.1
Average dollar volume
$1,935
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
7.42M
Valuation
12 metricsP / E (TTM)
1.6
Trailing earnings · reciprocal yield 62.9%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 907.9%
P / book
0.3
reciprocal yield 328.9%
FCF yield
-11.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
146.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
4.7×
reciprocal yield 21.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
41.5%
Operating margin
-7.8%
Trailing 12 months
Net margin
16.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$895,045
Net income (TTM)
$1.85M
Trailing 12 months
Diluted EPS (TTM)
$0.11
FCF margin
-1.3%
Effective tax rate
0.0%
Growth
11 metricsRevenue growth YoY
-24.9%
Year over year
Net income growth YoY
+774.3%
Revenue (TTM)
$11.45M
Trailing 12 months
EPS growth YoY
+700.0%
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
+4.0%
Revenue CAGR (5Y)
+5.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
44.7%
Return on assets
24.6%
Debt / equity
—
Current ratio
2.6
EBITDA (TTM)
−$866,906
Free cash flow (TTM)
−$143,965
Quick ratio
1.9
Interest coverage
-55.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.34M
Total assets
$4.69M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$135,664
Capital expenditures (TTM)
$8,301
R&D (TTM)
$668,764
SG&A (TTM)
$4.97M
Stock compensation (TTM)
—
R&D / revenue
5.8%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
1.1%
Latest settlement · 46.6 days to cover
Days to cover
46.6d
Short-squeeze score
49 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged